Antimicrobial drug pricing

Avaneesh Kumar Pandey; Nusrat Shafiq; Ashish Kumar Kakkar; Samir Malhotra; Beth Woods; Christopher Little; Tom Rhodes; Harriet Tuson; Zeshan Riaz; Tom Ashfield; Michael Corley; Ioannis Baltas

doi:10.1038/s43856-024-00594-9

Antimicrobial drug pricing

Commun Med (Lond). 2024 Oct 11;4(1):198. doi: 10.1038/s43856-024-00594-9.

Authors

Affiliations

¹ Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
² Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. nusrat.shafiq.pgi@gmail.com.
³ Centre for Health Economics, University of York, York, UK. beth.woods@york.ac.uk.
⁴ Pfizer UK, Tadworth, UK.
⁵ Pfizer UK, Tadworth, UK. Harriet.Tuson@pfizer.com.
⁶ British Society for Antimicrobial Chemotherapy, London, UK. drashfield@gmail.com.
⁷ British Society for Antimicrobial Chemotherapy, London, UK.
⁸ Infection, Immunity & Inflammation Department, University College London Institute of Child Health, London, UK. ioannis.baltas@doctors.org.uk.
⁹ Department of Clinical Microbiology, University College London Hospitals NHS Foundation Trust, London, UK. ioannis.baltas@doctors.org.uk.

Abstract

Despite the constant development of antimicrobial resistance (AMR), few new antimicrobials are currently becoming available clinically. Alternative approaches, such as different mechanisms to fund their use, are being explored to encourage development of new antimicrobials.